Home
NICE Guidance
Published Guidance
Cabazitaxel for hormone-refractory metastatic prostate cancer previously treated with a docetaxel-containing regimen
Technology appraisal guidance [TA255]
Published date:
11 May 2012
Guidance
This guidance has been updated and replaced by
NICE technology appraisal guidance 391
.